Is cystatin C a better monitoring choice than creatinine on cagrilintide?

The case in front of me: cystatin C · creatinine · cagrilintide.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

What does each option buy me, and what does it cost me?

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Relative to absolute, worked

The last two rows describe the same finding. Only one of them is used in headlines.

The part that matters: delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

The short version: a small, well-chosen panel with a baseline beats a large one without.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Keep the full report, not the number. You will need the units and the interval later.

This is answerable, and the answer is mostly about which tests rather than how many.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Decide the action for each result before you order the test.

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Baseline first, then a repeat under identical conditions. Everything else is secondary.